[A21-116] Upadacitinib (atopic dermatitis) - Benefit assessment according to §35a Social Code Book V
Last updated 01.12.2021
Project no.:
A21-116
Commission:
Commission awarded on 01.09.2021 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Skin and hair
Indication:
Moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy
Result of dossier assessment:
- Adult women for whom 30 mg is the appropriate dose: hint of considerable added benefit
- Adult men for whom 30 mg is the appropriate dose: hint of major added benefit
- Adults for whom 15 mg is the appropriate dose: added benefit not proven
- Adolescents (12-17 years of age): added benefit not proven
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A21-16 | Upadacitinib (ankylosing spondylitis) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A21-15 | Upadacitinib (psoriatic arthritis) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A20-08 | Upadacitinib (rheumatoid arthritis) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A23-38 | Upadacitinib (Crohn disease) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A22-91 | Upadacitinib (ulcerative colitis) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A22-92 | Upadacitinib (axial spondyloarthritis) - Benefit assessment according to §35a Social Code Book V | Commission completed |